Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
David C. Hastings | Chief Financial Officer | 2024-02-02 | 9,593 | $2.31 | $22.18kSell |
Michael J. McElhaugh | Interim President CEO | 2024-02-02 | 10,164 | $2.31 | $23.50kSell |
Karen Sims | Chief Medical Officer | 2024-02-02 | 4,358 | $2.31 | $10.08kSell |
Michael J. Sofia | Chief Scientific Officer | 2024-02-02 | 9,982 | $2.31 | $23.08kSell |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Roivant Sciences Ltd | 21.64% | 38,847,462 | $106.83M | Insider |
Dexxon Holdings Ltd | 17.84% | 32,027,080 | $88.07M | Insider |
Vivek Ramaswamy | 8.95% | 16,068,455 | $44.19M | Insider |
Dexcel Pharma Technologies Ltd | 8.92% | 16,013,540 | $44.04M | Insider |
Svf Investments Uk Ltd | 8.92% | 16,013,540 | $44.04M | Insider |
Viking Global Performance LLC | 8.92% | 16,013,540 | $44.04M | Insider |
Rose Sharon Shabet | 8.92% | 16,013,540 | $44.04M | Insider |
Patrick MacHado | 8.92% | 16,013,540 | $44.04M | Insider |
Andrew Lo | 8.92% | 16,013,540 | $44.04M | Insider |
Viking Global Investors LP | 8.92% | 16,013,540 | $44.04M | Insider |